EffRx Pharmaceuticals has an experienced management team with savvy knowledge of the biopharma industry and international life sciences experience across several therapeutic areas.
EffRx leverages this collective expertise in medical affairs, clinical development, regulatory affairs, market access, commercialization and operations to build an international pharmaceutical business through superior products and successful partnerships.
Chief Executive Officer
Mr. Bosisio, CEO of EffRx Pharmaceuticals since 2016, has a solid experience across different therapeutic areas in bringing medicines from development stage to the market. He served as Chief Commercial Officer for Tissot Medical Research and as EMEA Marketing Director for Alexion. During his 9 years tenure with Amgen he built from scratch the international commercial infrastructure for the flagship drug denosumab, launched Prolia®, optimized Aranesp® and launched Mimpara®. At PwC Switzerland he led Marketing and Business Development for its major practice. Earlier in his career he set up the commercial organization and led Marketing & Sales for a start-up.
Mr. Bosisio holds a BSc in Economics & Business Administration and has earned an MBA from HEC School of Management Paris.
Peter Lichtlen, MD, PhD
Chief Medical Advisor
Dr. Lichtlen, Chief Medical Advisor at EffRx, previously served as Chief Medical Officer (CMO) at Sucampo Pharmaceuticals, Inc (Nasdaq: SCMP) until its $1.2B acquisition by Mallinckrodt in early 2018.
He is also a founder and the CMO at Numab Therapeutics AG in Switzerland. Prior to co-founding Numab Therapeutics AG in 2011, Dr. Lichtlen was the Head of Clinical R&D at ESBATech AG (acquired by Alcon/Novartis in 2009) until end of 2010. Besides his CMO role at Numab Therapeutics AG and his consultancy role at EffRx, Dr. Lichtlen is also a member of the Board of Directors at Lysogene SA (EN Paris: LYS), a clinical-stage gene therapy company active in the area of rare neurodegenerative diseases.
Dr. Lorraine Zakin, MD
Director Medical Affairs
Dr. Lorraine Zakin, Director Medical Affairs at EffRx Pharmaceuticals, received her clinical training as a general surgeon and practiced at major hospitals in Argentina and France before entering the pharmaceutical industry 11 years ago.
During her career, she has held positions of growing responsibility in medical affairs and clinical development at local, regional and global levels within global pharma companies such as Onxeo (prior Bioalliance Pharma) and Vifor Pharma simultaneously gaining working experience across several therapeutic areas such as cardiology, oncology and women’s health.
Director Regulatory Affairs
Ms. Christiane Sievert is the Director of Regulatory Affairs at EffRx. She most recently worked at Stragen Pharma as VP & Head of Regulatory Affairs. Her Regulatory Affairs experience spans the pharmaceutical value chain, from early development to life-cycle management. Further, she brings proven, in-depth knowledge in RA across international markets, firsthand experience in interacting with Health Authorities, as well as expertise in setting up, leading & optimizing RA processes and infrastructures.
Ms. Sievert holds a Dipl. Ing. in Pharmaceutical Chemistry and has a broad therapeutic area experience in both blue-chip as well as smaller entrepreneurial biopharmaceutical companies.
Executive Vice President Corporate Development
Mr. Victor Papavasileiou has over 10 years’ experience in the pharma and biotech industry in business, corporate development and strategy. He has a track record of developing profitable product portfolios in therapeutic areas of strategic interest through M&A and licensing and specializes in SME turnaround and growth.
Prior to joining EffRx, he led business development at Lacer, a major Spanish pharmaceutical company, and more recently in Navamedic, a listed pharmaceutical and Medtech company covering the Nordic markets.
Victor holds an M.Sc. in Biotechnology and Biochemical Engineering from UCL in London, a Professional Doctorate in Engineering from the TU Delft in the Netherlands and an MBA from Kellogg.
Dr. Nathalie Véron
Director Technical Operations
Dr. Nathalie Véron, Director Technical Operations at EffRx, is responsible for the operational activities such as product supply, quality assurance and IP management.
Prior to joining EffRx, she has held various local and global, cross-functional leadership positions in Manufacturing Science and Technology at F. Hoffmann-La Roche, Technical Operations. In addition, she significantly contributed to Digital Supply Chain and Quality Transformation projects in the pharmaceutical industry.
Dr. Véron is a pharmacist by education, who graduated from the University of Freiburg, Germany. She holds a PhD in Biology from the Free University Berlin, Germany and has over 10 years of experience as a Biomedical Scientist
Chief Financial Officer
Mr. Paolo Agnoluzzi became the Chief Financial Officer in 2017. Since joining, he successfully executed a number of debt and equity transactions, including a capital increase.
Most recently, Mr. Agnoluzzi served as Finance Director for VistaJet Group Holding SA. His responsibilities included acting as deputy CFO, leading the financial planning and analysis group, heading the treasury function and directing special projects within Finance.
Prior to VistaJet, Mr. Agnoluzzi held the position of Director Finance Europe and Commercial Head DACH Region at Endocyte Europe GmbH. Previously to Endocyte, he spent 20 years at Amgen serving various senior financial positions, including among others, Head of Finance Oncology, Bone and New Products and Director Finance & Administration.
Director International Marketing
Michael Schmid is the International Marketing Director of EffRx.
Prior to joining EffRx, Mr. Schmid served as Global Brand Lead at Takeda Pharmaceuticals, where he was responsible for the world’s top-selling medicinal calcium and vitamin D supplement. Other previous positions include Brand Leader Specialist Accounts, Commercial Operations Emerging Markets (Takeda), and Senior Global Brand Manager at Nycomed. Michael studied pharmacy at the ETH in Zurich.
Mr. Schmid has over 20 years of experience in the pharmaceutical industry, working across a wide range of therapeutic areas, including osteoporosis, gastroenterology and pain management.